About Summit Therapeutics Inc.
https://www.summittxinc.comSummit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI).
CEO
Robert W. Duggan
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 114
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Guggenheim
Buy
HC Wainwright & Co.
Buy
Citigroup
Buy
Goldman Sachs
Buy
Jefferies
Buy
JMP Securities
Market Outperform
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
BAKER BROS. ADVISORS LP
Shares:33.72M
Value:$595.21M
VANGUARD GROUP INC
Shares:11.38M
Value:$200.85M
FMR LLC
Shares:8.92M
Value:$157.4M
Summary
Showing Top 3 of 252
About Summit Therapeutics Inc.
https://www.summittxinc.comSummit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI).
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $234.17M ▼ | $-231.79M ▲ | 0% | $-0.31 ▲ | $-231.75M ▲ |
| Q2-2025 | $0 | $568.4M ▲ | $-565.71M ▼ | 0% | $-0.76 ▼ | $-565.67M ▼ |
| Q1-2025 | $0 | $66.85M ▲ | $-62.91M ▼ | 0% | $-0.09 ▼ | $-62.89M ▼ |
| Q4-2024 | $0 | $65.61M ▲ | $-61.2M ▼ | 0% | $-0.08 ▼ | $-61.15M ▼ |
| Q3-2024 | $0 | $58.38M | $-56.25M | 0% | $-0.08 | $-53.52M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $238.88M ▼ | $261.73M ▼ | $69.47M ▲ | $192.26M ▼ |
| Q2-2025 | $297.87M ▼ | $324.04M ▼ | $64.6M ▲ | $259.44M ▼ |
| Q1-2025 | $361.31M ▼ | $383.82M ▼ | $39.49M ▼ | $344.33M ▼ |
| Q4-2024 | $412.35M ▼ | $435.56M ▼ | $46.81M ▼ | $388.75M ▼ |
| Q3-2024 | $486.9M | $502.85M | $64.93M | $437.92M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-231.79M ▲ | $-95.02M ▼ | $-1.29M ▼ | $34.66M ▲ | $-59.32M ▼ | $-95.09M ▼ |
| Q2-2025 | $-565.71M ▼ | $-66.74M ▼ | $150.81M ▼ | $2.22M ▼ | $86.35M ▼ | $-66.74M ▼ |
| Q1-2025 | $-62.91M ▼ | $-61.17M ▼ | $160.11M ▲ | $7.68M ▲ | $106.66M ▲ | $-61.59M ▼ |
| Q4-2024 | $-61.2M ▼ | $-48.67M ▼ | $83.48M ▲ | $-23.61M ▼ | $11.09M ▼ | $-48.69M ▼ |
| Q3-2024 | $-56.25M | $-30.45M | $-108.61M | $204.14M | $65.34M | $-30.36M |
Revenue by Products
| Product | Q1-2022 | Q2-2022 | Q3-2022 | Q4-2022 |
|---|---|---|---|---|
 License and Service | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q4-2021 | Q3-2022 | Q1-2022 | Q2-2022 |
|---|---|---|---|---|
 Latin America | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Robert W. Duggan
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 114
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Guggenheim
Buy
HC Wainwright & Co.
Buy
Citigroup
Buy
Goldman Sachs
Buy
Jefferies
Buy
JMP Securities
Market Outperform
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
BAKER BROS. ADVISORS LP
Shares:33.72M
Value:$595.21M
VANGUARD GROUP INC
Shares:11.38M
Value:$200.85M
FMR LLC
Shares:8.92M
Value:$157.4M
Summary
Showing Top 3 of 252